Literature DB >> 17828817

Regulatory T cells in viral hepatitis.

Eva Billerbeck1, Tobias Bottler, Robert Thimme.   

Abstract

The pathogenesis and outcome of viral infections are significantly influenced by the host immune response. The immune system is able to eliminate many viruses in the acute phase of infection. However, some viruses, like hepatitis C virus (HCV) and hepatitis B virus (HBV), can evade the host immune responses and establish a persistent infection. HCV and HBV persistence is caused by various mechanisms, like subversion of innate immune responses by viral factors, the emergence of T cell escape mutations, or T cell dysfunction and suppression. Recently, it has become evident that regulatory T cells may contribute to the pathogenesis and outcome of viral infections by suppressing antiviral immune responses. Indeed, the control of HCV and HBV specific immune responses mediated by regulatory T cells may be one mechanism that favors viral persistence, but it may also prevent the host from overwhelming T cell activity and liver damage. This review will focus on the role of regulatory T cells in viral hepatitis.

Entities:  

Mesh:

Year:  2007        PMID: 17828817      PMCID: PMC4611764          DOI: 10.3748/wjg.v13.i36.4858

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  64 in total

1.  Inducing and expanding regulatory T cell populations by foreign antigen.

Authors:  Karsten Kretschmer; Irina Apostolou; Daniel Hawiger; Khashayarsha Khazaie; Michel C Nussenzweig; Harald von Boehmer
Journal:  Nat Immunol       Date:  2005-10-23       Impact factor: 25.606

Review 2.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  From vanilla to 28 flavors: multiple varieties of T regulatory cells.

Authors:  Ethan M Shevach
Journal:  Immunity       Date:  2006-08       Impact factor: 31.745

4.  Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.

Authors:  Dongping Xu; Junliang Fu; Lei Jin; Hui Zhang; Chunbao Zhou; Zhengsheng Zou; Jing-Min Zhao; Bin Zhang; Ming Shi; Xilai Ding; Zirong Tang; Yang-Xin Fu; Fu-Sheng Wang
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

5.  T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.

Authors:  Tobias Boettler; Hans Christian Spangenberg; Christoph Neumann-Haefelin; Elisabeth Panther; Simonetta Urbani; Carlo Ferrari; Hubert E Blum; Fritz von Weizsäcker; Robert Thimme
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells.

Authors:  Ye Zheng; Steven Z Josefowicz; Arnold Kas; Tin-Tin Chu; Marc A Gavin; Alexander Y Rudensky
Journal:  Nature       Date:  2007-01-21       Impact factor: 49.962

Review 7.  IDO expression by dendritic cells: tolerance and tryptophan catabolism.

Authors:  Andrew L Mellor; David H Munn
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

8.  Modulation of tryptophan catabolism by regulatory T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Kwang Woo Hwang; Ciriana Orabona; Carmine Vacca; Roberta Bianchi; Maria Laura Belladonna; Maria Cristina Fioretti; Maria-Luisa Alegre; Paolo Puccetti
Journal:  Nat Immunol       Date:  2003-10-26       Impact factor: 25.606

9.  Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.

Authors:  WanJun Chen; Wenwen Jin; Neil Hardegen; Ke-Jian Lei; Li Li; Nancy Marinos; George McGrady; Sharon M Wahl
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

10.  Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression.

Authors:  Tobias Bopp; Christian Becker; Matthias Klein; Stefan Klein-Hessling; Alois Palmetshofer; Edgar Serfling; Valeska Heib; Marc Becker; Jan Kubach; Steffen Schmitt; Sabine Stoll; Hansjörg Schild; Martin S Staege; Michael Stassen; Helmut Jonuleit; Edgar Schmitt
Journal:  J Exp Med       Date:  2007-05-14       Impact factor: 14.307

View more
  22 in total

1.  Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies.

Authors:  Yanfang Jiang; Wanyu Li; Lei Yu; Jingjing Liu; Guijie Xin; Hongqing Yan; Pinghui Sun; Hong Zhang; Damo Xu; Junqi Niu
Journal:  Cell Mol Immunol       Date:  2010-10-04       Impact factor: 11.530

2.  Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis.

Authors:  Shaoyong Li; Lianne E M Vriend; Imad A Nasser; Yury Popov; Nezam H Afdhal; Margaret J Koziel; Detlef Schuppan; Mark A Exley; Nadia Alatrakchi
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

Review 3.  Host-virus interactions in hepatitis B virus infection.

Authors:  Luca G Guidotti; Masanori Isogawa; Francis V Chisari
Journal:  Curr Opin Immunol       Date:  2015-07-15       Impact factor: 7.486

4.  NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody.

Authors:  Vitaly Ablamunits; Octavian Henegariu; Paula Preston-Hurlburt; Kevan C Herold
Journal:  Eur J Immunol       Date:  2011-06-06       Impact factor: 5.532

Review 5.  Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets.

Authors:  Tamara Severi; Hannah van Malenstein; Chris Verslype; Jos F van Pelt
Journal:  Acta Pharmacol Sin       Date:  2010-10-18       Impact factor: 6.150

Review 6.  Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it?

Authors:  A Boasso; G M Shearer; C Chougnet
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

Review 7.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

8.  CD19+CD24hiCD38hi regulatory B cells: a potential immune predictive marker of severity and therapeutic responsiveness of hepatitis C.

Authors:  Qiannan Fang; Yanan Deng; Rongzhen Liang; Yongyu Mei; Zhaoxia Hu; Julie Wang; Jianbo Sun; Xiaohong Zhang; Joseph A Bellanti; Song Guo Zheng
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

9.  Phenotypic and functional alterations of primary human PBMCs induced by HCV non-enveloped capsid-like particles uptake.

Authors:  Polyxeni P Doumba; Elisavet Serti; Maria Boutsikou; Manousos M Konstadoulakis; Urania Georgopoulou; John Koskinas
Journal:  Cell Mol Life Sci       Date:  2013-05-05       Impact factor: 9.261

10.  Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection.

Authors:  Shuo Li; Stefan Floess; Alf Hamann; Silvana Gaudieri; Andrew Lucas; Margaret Hellard; Stuart Roberts; Geza Paukovic; Magdalena Plebanski; Bruce E Loveland; Campbell Aitken; Simon Barry; Louis Schofield; Eric J Gowans
Journal:  PLoS Pathog       Date:  2009-12-24       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.